PRINCETON, N.J., March 6 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. , a provider of advanced wound care products, announced today that seven abstracts detailing the clinical usage of its newly released MEDIHONEY Wound & Burn Dressings with Active Leptospermum Honey were accepted for presentation at the upcoming annual Symposium on Advanced Wound Care conference, held this year between April 24 - 27 in San Diego, CA. Additionally, the company has announced that two of the abstracts will be presented as oral presentations to a general assembly of the conference attendees.
Chairman and CEO Ed Quilty said, "MEDIHONEY dressings continue to receive positive levels of acceptance by clinicians worldwide and has become the most talked about treatment for hard-to-heal wounds in many forums. Having several abstracts related to MEDIHONEY dressing accepted in the largest annual international conference of its kind validates our very high expectations, and helps to further our goal of advancing wound care by uncovering technological innovations, empowering caregivers, and focusing on unmet patient needs."
The abstracts include the following:
"The Importance of Medical Grade Honey Rather than Table Honey in the Treatment of Wounds"; Cooper RA, Jenkins L, Rowlands R. (oral presentation)
"The Inhibition of Biofilms of Pseudomonas Aeruginosa with Manuka Honey"; Cooper RA, Jenkins L, Rowlands R. (oral presentation)
"Manuka Honey Alginate Wound Dressing Facilitates Healing Of Chronic Diabetic Lower Extremity Ulcerations"; Robert Frykberg, DPM, MPH, Arthur Tallis, DPM, Cherese Thomas-Ramoutar, DPM, Edward Tierney, DPM.
"Comparison of Honey-Impregnated Calcium Alginate Dressings to Non-Impregnated Calcium Alginate Dressings on Wound Healing"; Catherine T. Milne, APRN, MSN, CWOCN; Connecticut Clinical Nursing Associates, LLC, Bristol Hospital Wound, Ostomy, Lymphedema Center, Bristol, CT.
"It Looks Like Honey. It Smells Like Honey. Yes, It Is Honey!"; Becky Strilko, RN, BSN, CWOCN, APN, Christine Barkauskas, RN, BA, CWOCN, APN, Andrea Mcintosh, RN, BSN, CWOCN, APN, Noreen Reaney, RN, BSN, Wound Ostomy and Continence Student, Provena Saint Joseph Medical Center, Joliet, IL.
"The Influence of Catalase on the Antibacterial Activity of Honey"; Cooper RA, Jenkins L, Rowlands R.
"The Effects of a Leptospermum Honey Dressing on Methicillin-Resistant Staphylococcus Aureus (MRSA) Biofilms Using a Well Established Porcine Wound Infection model"; Stephen C. Davis, Yan Rivas, Joel Gil, Roberto Perez, Jose Valdes, Robert Kirsner, Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced wound-care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey-based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.
About the SAWC
The SAWC is the Annual Symposium for the Association for Advancement of Wound Care and the Wound Healing Society Meeting. It is an annual conference specifically dedicated to the wounds and wound-related issues. The largest conference of its kind drawing attendees from all over the world, the meeting is an informational hub for multidisciplinary wound care clinicians and researchers. The SAWC/WHS comprises four days of educational sessions, meetings, interactive events, and social gatherings, including a pre- and post-conference.
Forward-looking Statements
Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements which may be made in this release or which are otherwise made by or on behalf of the Company. Factors which may affect the Company's results include, but are not limited to, product demand, market acceptance, impact of competitive products and prices, product development, completion of an acquisition, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements Include but are not limited to, those discussed in the Company's filings with the Securities and Exchange Commission.
r.barrio@allencaron.comequilty@dermasciences.combrian@allencaron.com
CONTACT: Edward J. Quilty, Chairman and CEO of Derma Sciences Inc,
+1-609-514-4744, equilty@dermasciences.com; or US Investors, Rudy Barrio,
r.barrio@allencaron.com, or media, Brian Kennedy, brian@allencaron.com,
both of Allen & Caron Inc, +1-212-691-8087
Web site: http://www.dermasciences.com/
